Teva Pharmaceuticals and Celltrion jointly announce Truxima (rituximab-abbs, ritoxinocoid) in the U.S. market

TevaPharmaceutical
s (http://(Teva) and partner Korea Biopharmaceutical(http://Celltrion recently announced the launch of Truxima (rituximab-abbs, rituximab-abbs) in the U.SmarketThe Truxima is a biosimilar of Roche ace biologicRitutRite (Mera, generic name: rituximab, ritoxima) with a complete oncology labelIn the United States, Truxima is the first lituxima biosimilar approved by theFDA(http://, and the first biosimilar approved by the FDA to treat NHLTruxima received FDA approval at the end of November 2018 based on a comprehensive package that includes basic and extensiveanalysis(http://characterization, non-clinical data, clinical pharmacology, immunoogenics, clinical efficacy, and safety data In May 2019, the FDA approved Truxima to comply with reference drug (http:// Rituxan for the treatment of all oncology indications in NHL and CLL 　　Under the
settlement with Roche's Genentech (http:// Teva and Celltrion currently hold a pending application to the FDA for the treatment of rheumatoid arthritis (RA), granuloma polysotitis (GPA) and microscopic polybanicitis (MPA), as well as a permit from Genetmet to expand the Truxima label to include the above-mentioned indications in the second quarter of 2020 　　In terms of pricing, Truxima's wholesale procurement costs (WAC) are 10 per cent lower than The Roche brand's Name Rituxan Truxima 100mg bottlewaC is $845.55 and 500mg bottled WAC is $4227.75 However, the actual cost of payment to patients and supply (http:// providers is expected to be lower than that of the WAC